Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
MONOPAR THERAPEUTICS INC (MNPR) Stock Price & Overview
NASDAQ:MNPR • US61023L2079
Current stock price
53.25 USD
+1.1 (+2.11%)
At close:
53.25 USD
0 (0%)
After Hours:
The current stock price of MNPR is 53.25 USD. Today MNPR is up by 2.11%. In the past month the price decreased by -3.41%. In the past year, price increased by 18.44%.
MNPR Key Statistics
52-Week Range28.4 - 105
Current MNPR stock price positioned within its 52-week range.
1-Month Range50.07 - 60.08
Current MNPR stock price positioned within its 1-month range.
- Market Cap
- 356.243M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.85
- Dividend Yield
- N/A
MNPR Stock Performance
Today
+2.11%
1 Week
+0.09%
1 Month
-3.41%
3 Months
-11.81%
Longer-term
6 Months -38.20%
1 Year +18.44%
2 Years +1,642.76%
3 Years +988.96%
5 Years +86.51%
10 Years N/A
MNPR Stock Chart
MNPR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MNPR. When comparing the yearly performance of all stocks, MNPR turns out to be only a medium performer in the overall market: it outperformed 45.96% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
MNPR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MNPR. While MNPR has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MNPR Earnings
Next Earnings DateMay 11, 2026
Last Earnings DateMar 27, 2026
PeriodQ4 / 2025
EPS Reported-$0.64
Revenue Reported
EPS Surprise -27.29%
Revenue Surprise %
MNPR Forecast & Estimates
20 analysts have analysed MNPR and the average price target is 115.04 USD. This implies a price increase of 116.04% is expected in the next year compared to the current price of 53.25.
Analysts
Analysts84
Price Target115.04 (116.04%)
EPS Next Y-109.4%
Revenue Next YearN/A
MNPR Index Membership
MNPR is currently included in the following stock indexes tracked on ChartMill.
MNPR Financial Highlights
Over the last trailing twelve months MNPR reported a non-GAAP Earnings per Share(EPS) of -1.85. The EPS increased by 55.1% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-13.72M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.75% | ||
| ROE | -9.95% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%76.73%
Sales Q2Q%N/A
EPS 1Y (TTM)55.1%
Revenue 1Y (TTM)N/A
MNPR Ownership
Ownership
Inst Owners83.17%
Shares6.69M
Float5.10M
Ins Owners6.82%
Short Float %33.79%
Short Ratio9.27
MNPR Industry Overview
MNPR operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
MNPR Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MNPR
Company Profile
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois and currently employs 16 full-time employees. The company went IPO on 2019-12-19. The firm developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Company Info
IPO: 2019-12-19
MONOPAR THERAPEUTICS INC
1000 Skokie Blvd Ste 350
Wilmette ILLINOIS 60091 US
CEO: Chandler Robinson
Employees: 16
Phone: 18473880349
MONOPAR THERAPEUTICS INC / MNPR FAQ
What does MONOPAR THERAPEUTICS INC do?
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois and currently employs 16 full-time employees. The company went IPO on 2019-12-19. The firm developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
What is the stock price of MONOPAR THERAPEUTICS INC today?
The current stock price of MNPR is 53.25 USD. The price increased by 2.11% in the last trading session.
Does MONOPAR THERAPEUTICS INC pay dividends?
MNPR does not pay a dividend.
What is the ChartMill rating of MONOPAR THERAPEUTICS INC stock?
MNPR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of MONOPAR THERAPEUTICS INC (MNPR)?
MONOPAR THERAPEUTICS INC (MNPR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.85).
What is the outstanding short interest for MONOPAR THERAPEUTICS INC?
The outstanding short interest for MONOPAR THERAPEUTICS INC (MNPR) is 33.79% of its float.